Tong, Gary <br/><br/>
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.  [electronic resource] 

 -  British journal of clinical pharmacology  Jan 2013 
 - 136-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2125 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2125.2012.04339.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alzheimer Disease--drug therapy<br/>Amyloid Precursor Protein Secretases--antagonists & inhibitors<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Oxadiazoles--adverse effects<br/>Sulfonamides--adverse effects